Drug
AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M
CI-DRUG-00000025Explore in graph →NCIt C132025 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 11, 2015 |
| Malignant Lung Neoplasm | Phase1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 1, 2017 |
ComputedclinicaltrialsProvenance
- Source
- clinicaltrials
- Layer
- derived (computed by CancerIndex)
Data updated 19 hours agoSource updated unknown
Curated evidence
Clinical evidence (1)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37041472
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MET Exon 14 Skipping Mutation + MET Overexpression1 | ||||||||
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | ||||||||
Clinical trials
Trials with this intervention (2)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02478866 | Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02929290 | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | unknown | Phase 1 |